KVISTGAARD, Denmark, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Copenhagen:BAVA) announced today that BARDA (Biomedical Advanced Research and Development Authority) has exercised the next option under the contract for the development of a freeze-dried version of Bavarian Nordic’s IMVAMUNE(R) smallpox vaccine.
